Supply of cannabis oil from Stenocare affected in Denmark

12 July 2019

Several consignments of cannabis oil from the Danish firm Stenocare have been placed in quarantine and taken off the market because the cannabis used in the oil was cultivated in non-approved facilities. The supply of cannabis oil in Denmark will therefore be affected.

The Canadian firm Canntrust, which supplies cannabis oil to Stenocare, cultivated the cannabis in facilities that were not approved for cultivating cannabis by the Canadian authorities, Health Canada, until April 2019. Several consignments of cannabis oil manufactured based on the cannabis cultivated in the non-approved facilities have therefore been placed in quarantine and take off the market. This means that there will be delays in the supply of cannabis oil from Stenocare until the firm can procure new consignments from Canada that have been cultivated in approved facilities.

Poses no health risk

According to information in the possession of the Danish Medicines Agency, there are no indications that the cannabis cultivated in the non-approved facilities is of a lower quality which could pose a health risk to patients. The decision to place the oil in quarantine and take it off the market has been taken solely as a safety precaution.

Doctors will continue to be able to prescribe magistral preparations of oral medications containing cannabis extract.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.